GVHD occurs when the donor T cells mount an immune response against the recipient’s organs and tissues.
Despite the logistical advantages of allogeneic cell therapies, a major drawback is the potential immunological issues caused by infusing allogeneic cells in the patient.
TCR Biotherapeutics announced today that it has joined BioForward Wisconsin, an organization that supports the growth of Wisconsin’s biohealth industry.
TCR Biotherapeutics has moved its research laboratory and offices to the Accelerator Building at University of Wisconsin-Milwaukee’s Innovation Campus.